Dr. Reed has more than 25+ years of industry experience in chemistry, manufacturing and control (CMC) guiding API development, drug product design and development, pharmaceutical product and process characterization, technology transfer and regulatory strategy and submissions, including 12 years with liposomal products. He previously served as Senior Vice President of CMC and Technical Operations at Celsion Corporation, Vice President of Pharmaceutical Operations at XenoPort, Senior Director at Pharmaceutical Research and Development at Merck and Company, and Research Scientist at The Liposome Company. While at Merck & Co., Dr. Reed directed the CMC activities of many late stage products, such as Crixivan®, Singulair® and Januvia®. At XenoPort, Dr. Reed oversaw CMC activities for their lead candidate, Horizant®. Overall, Dr. Reed has supported the commercialization of 25 drugs for global registration. Dr. Reed received his PhD from The University of North Carolina at Chapel Hill, and was awarded a NIH Post Doctoral Fellow at Princeton University. He is an American Association of Pharmaceutical Scientists Fellow and serves on the Industry Advisory Board to University of the Pacific School of Pharmacy.

Biotechnology, Clinical Research, Clinical Trials